Ra Capital Management, L.P. - Jun 14, 2022 Form 4 Insider Report for Vor Biopharma Inc. (VOR)

Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Stock symbol
VOR
Transactions as of
Jun 14, 2022
Transactions value $
$0
Form type
4
Date filed
6/17/2022, 04:30 PM
Previous filing
Jun 15, 2022
Next filing
Jun 21, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VOR Stock Option (Right to Buy) Award $0 +16.9K $0.00 16.9K Jun 14, 2022 Common Stock 16.9K $4.26 See footnote F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F2 This option was granted to Joshua Resnick, a Managing Director of the Adviser who serves on the Issuer's board of directors, pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to Mr. Resnick's continued service as a director through such date.
F3 Under Mr. Resnick's arrangement with the Adviser, Mr. Resnick holds the option for the benefit of the Fund and the Nexus Fund. Mr. Resnick is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

Remarks:

Mr. Joshua Resnick, a Managing Director of the Adviser, serves on the Issuer's board of directors.